Based on the SurModics Inc stock forecast from 1 analysts, the average analyst target price for SurModics Inc is USD 43.00 over the next 12 months. SurModics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of SurModics Inc is Slightly Bearish, which is based on 6 positive signals and 8 negative signals. At the last closing, SurModics Inc’s stock price was USD 28.49. SurModics Inc’s stock price has changed by -2.83% over the past week, +3.56% over the past month and +5.52% over the last year.
No recent analyst target price found for SurModics Inc
No recent average analyst rating found for SurModics Inc
Company Overview SurModics Inc
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. Read Less
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates thr...Read More
Frequently Asked Questions About SurModics Inc (SRDX) Stock
Based on ratings from 1 analysts SurModics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on SRDX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for SRDX is USD 43.00 over the next 12 months. The maximum analyst target price is USD 43 while the minimum anlayst target price is USD 43.
SRDX stock's Price/Earning ratio is 43.13.
Our analysis grades SRDX stock's Price / Earning ratio at F. This means that SRDX stock's Price/Earning ratio is above 67% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this SRDX may be a overvalued for its sector.
The last closing price of SRDX's stock was USD 28.49.
The most recent market capitalization for SRDX is USD 0.42B.
Based on targets from 1 analysts, the average taret price for SRDX is projected at USD 43.00 over the next 12 months.
This means that SRDX's stock price may go up by +50.93% over the next 12 months.
We can't find any ETFs which contains SurModics Inc's stock.
As per our most recent records SurModics Inc has 389 Employees.
SurModics Inc's registered address is 9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523.
You can get more information about it from SurModics Inc's website at https://www.surmodics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About SurModics Inc (SRDX) Stock
Based on ratings from 1 analysts SurModics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on SRDX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for SRDX is USD 43.00 over the next 12 months. The maximum analyst target price is USD 43 while the minimum anlayst target price is USD 43.
SRDX stock's Price/Earning ratio is 43.13.
Our analysis grades SRDX stock's Price / Earning ratio at F. This means that SRDX stock's Price/Earning ratio is above 67% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this SRDX may be a overvalued for its sector.
The last closing price of SRDX's stock was USD 28.49.
The most recent market capitalization for SRDX is USD 0.42B.
Based on targets from 1 analysts, the average taret price for SRDX is projected at USD 43.00 over the next 12 months.
This means that SRDX's stock price may go up by +50.93% over the next 12 months.
We can't find any ETFs which contains SurModics Inc's stock.
As per our most recent records SurModics Inc has 389 Employees.
SurModics Inc's registered address is 9924 West 74th Street, Eden Prairie, MN, United States, 55344-3523.
You can get more information about it from SurModics Inc's website at https://www.surmodics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SRDX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
